DK2004676T3 - Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf - Google Patents
Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf Download PDFInfo
- Publication number
- DK2004676T3 DK2004676T3 DK07705325.4T DK07705325T DK2004676T3 DK 2004676 T3 DK2004676 T3 DK 2004676T3 DK 07705325 T DK07705325 T DK 07705325T DK 2004676 T3 DK2004676 T3 DK 2004676T3
- Authority
- DK
- Denmark
- Prior art keywords
- 9hivl
- emb
- polypeptide
- dbj
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (18)
1. Polypeptid bestående af fra 30-45 aminosyrer, hvilket polypeptid omfatter SEQ ID NO: 1 eller en sekvens med mindst 85 % homologi med SEQ ID NO: 1: SEQ ID NO: 1 GDTWAGVEAIIRILQQLLFIHFRIGCQHSR hvor polypeptidet er immunogent for en HIV-stamme hos et hvirveldyr, der udtrykker et større histokompatibilitetskompleks- (MHC) allel.
2. Polypeptid ifølge krav 1, hvilket polypeptid omfatter en cytotoksisk T-lymfocyt (CTL), CD8+ T-celle- og/eller CD4+ T-celleepitop.
3. Polypeptid ifølge et hvilket som helst af de foregående krav, hvor homologien i alt væsentligt er 100 %.
4. Immunogent multi-epitoppolypeptid omfattende to eller flere polypeptider som defineret i et hvilket som helst af de foregående krav.
5. Polypeptidsanmiensætning, der omfatter to eller flere polypeptider, der er immunogene for en HIV-stamme hos et hvirveldyr, hvor ét af de to eller flere polypeptider er som defineret i et hvilket som helst af de foregående krav.
6. Polypeptidsammensætning ifølge krav 5, der endvidere omfattet ét eller flere polypeptider, der ikke har flere end 50 aminosyrer, hvor hvert polypeptid omfatter én eller flere sekvenser med 85 % eller større homologi med en hvilken som helst af SEQ ID NO: 2, SEQ ID NO: 3 eller SEQ ID NO: 4.
7. Polypeptidsammensætning ifølge krav 6, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4 eller en sekvens med 85 % eller større homologi med SEQ ID NO: 4.
8. Polypeptidsammensætning ifølge krav 7, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4 eller en sekvens med 95 % eller større homologi med SEQ ID NO: 4.
9. Polypeptidsammensætning ifølge krav 8, hvori sammensætningen omfatter et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 1; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 2; et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 3; og et polypeptid, der ikke har flere end 50 aminosyrer og omfatter SEQ ID NO: 4.
10. Polypeptid ifølge krav 1-4 eller polypeptidsammensætning ifølge krav 5-9, der er immunogen for en flerhed af HIV-stammer.
11. Polypeptid ifølge krav 1-4, eller polypeptidsammensætning som defineret i krav 5-10 til anvendelse i medicin.
12. Fremgangsmåde til fremstilling af et polypeptid som defineret i krav 1-4, hvilken fremgangsmåde omfatter kombinering af to eller flere epitoper for at danne polypeptidet.
13. Polypeptidkonstrukt, hvilket konstrukt omfatter et polypeptid som defineret i krav 1-4 og en bærer.
14. Fremgangsmåde til fremstilling af et polypeptidkonstrukt som defineret i krav 13, hvilken fremgangsmåde omfatter kombinering af polypeptidet med bæreren.
15. Polypeptidkonstrukt eller fremgangsmåde ifølge krav 13 eller krav 14, hvor bæreren er et molekyle, og fortrinsvis hvor bæreren omfatter et adjuvans og/eller en excipiens.
16. Medikament eller vaccinesammensætning til anvendelse i behandling eller forebyggelse af en HIV-virusinfektion, omfattende et polypeptid ifølge krav 1-4, en polypeptidsammensætning ifølge krav 5-10, eller et polypeptidkonstrukt ifølge krav 13 og 15 og eventuelt en egnet excipiens og/eller adjuvans.
17. Fremgangsmåde til fremstilling af et medikament eller en vaccinesammensætning som defineret i krav 16, hvilken fremgangsmåde omfatter blanding af et polypeptid som defineret i et hvilket som helst af kravene 1-4 med en egnet excipiens og/eller adjuvans.
18. Polypeptid ifølge krav 1-4, polypeptidsammensætning ifølge krav 5-10 eller polypeptidkonstrukt ifølge krav 13 eller 15 til anvendelse i behandling eller forebyggelse af en HIV-virusinfektion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0604920A GB0604920D0 (en) | 2006-03-10 | 2006-03-10 | Peptide sequences and compositions |
| GB0614260A GB0614260D0 (en) | 2006-07-18 | 2006-07-18 | Peptide sequences and compositions |
| PCT/GB2007/000812 WO2007104932A2 (en) | 2006-03-10 | 2007-03-09 | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2004676T3 true DK2004676T3 (da) | 2017-02-20 |
Family
ID=38232608
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07705325.4T DK2004676T3 (da) | 2006-03-10 | 2007-03-09 | Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf |
| DK11167363.8T DK2392587T3 (da) | 2006-03-10 | 2007-03-09 | Peptidsekvenser og sammensætninger |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11167363.8T DK2392587T3 (da) | 2006-03-10 | 2007-03-09 | Peptidsekvenser og sammensætninger |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20100055119A1 (da) |
| EP (2) | EP2392587B1 (da) |
| JP (3) | JP2009529570A (da) |
| KR (1) | KR20080106467A (da) |
| CN (2) | CN102443052B (da) |
| AP (2) | AP3642A (da) |
| AU (1) | AU2007226430B2 (da) |
| BR (1) | BRPI0708708A2 (da) |
| CA (1) | CA2645342A1 (da) |
| DK (2) | DK2004676T3 (da) |
| EA (1) | EA019733B1 (da) |
| ES (2) | ES2616341T3 (da) |
| IL (2) | IL193965A0 (da) |
| MX (1) | MX2008011520A (da) |
| NO (1) | NO20083576L (da) |
| NZ (1) | NZ570708A (da) |
| PL (1) | PL2392587T3 (da) |
| SG (1) | SG170092A1 (da) |
| UA (1) | UA97800C2 (da) |
| WO (1) | WO2007104932A2 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| EP3077417A1 (en) | 2013-12-08 | 2016-10-12 | Peptcell Limited | Hiv antigens and antibodies and compositions, methods and uses thereof |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330359A3 (en) | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
| DE4141970C2 (de) | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
| JPH08504837A (ja) | 1993-10-14 | 1996-05-28 | 生化学工業株式会社 | 新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤 |
| EP0728764A4 (en) | 1993-10-19 | 1999-01-20 | Ajinomoto Kk | PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS |
| US5843724A (en) * | 1995-04-27 | 1998-12-01 | Rutgers University | Chimeric nucleic acids and proteins for inhibiting HIV-1 expression |
| EP0980388A1 (en) * | 1997-05-20 | 2000-02-23 | YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem | Vif-derived hiv protease inhibitors |
| ES2389519T3 (es) | 1997-09-18 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Casetes de inmunización de ADN de vif atenuados para vacunas genéticas |
| US6228128B1 (en) | 1997-11-10 | 2001-05-08 | Charlotte Johansen | Antimicrobial activity of laccases |
| US20030180314A1 (en) | 1998-07-10 | 2003-09-25 | Degroot Anne | Immunogenic, cross-clade, HIV peptides |
| US20020182222A1 (en) * | 1998-07-10 | 2002-12-05 | Groot Anne De | HIV vaccine candidate peptides |
| WO2000049038A2 (de) * | 1999-02-19 | 2000-08-24 | Ulrich Schubert | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |
| NO311807B1 (no) | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| WO2001024810A1 (en) * | 1999-10-05 | 2001-04-12 | Epimmune Inc. | Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
| WO2001055177A2 (en) | 2000-01-28 | 2001-08-02 | Statens Serum Institut | Methods to identify ctl epitopes of hiv |
| NO314587B1 (no) | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| AU2002211490A1 (en) * | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1490396A4 (en) | 2001-03-01 | 2006-04-19 | Us Gov Health & Human Serv | IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES |
| AU2002331599A1 (en) * | 2001-08-16 | 2003-03-03 | The General Hospital Corporation | Epitopes of human immunodeficiency virus-1 |
| RU2214274C2 (ru) | 2001-08-16 | 2003-10-20 | Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ | Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич |
| CA2357906A1 (en) | 2001-09-28 | 2003-03-28 | Institut Pasteur | Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections |
| AU2003299134A1 (en) | 2002-05-20 | 2004-04-23 | The General Hospital Corporation | Cytotoxic t-cell epitopes of hiv-1 virus |
| CA2500715A1 (en) | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Hla binding peptides and their uses |
| US20070054262A1 (en) * | 2003-03-28 | 2007-03-08 | Baker Denise M | Methods of identifying optimal variants of peptide epitopes |
| BRPI0414443A (pt) * | 2003-09-17 | 2006-11-21 | Univ Duke | imunógenos consensuais/ancestrais |
| BRPI0514447B8 (pt) * | 2004-08-17 | 2021-05-25 | Centre Nat Rech Scient | uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina |
| CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
-
2007
- 2007-03-09 ES ES07705325.4T patent/ES2616341T3/es active Active
- 2007-03-09 CN CN201110312512.8A patent/CN102443052B/zh not_active Expired - Fee Related
- 2007-03-09 EP EP11167363.8A patent/EP2392587B1/en active Active
- 2007-03-09 US US12/282,132 patent/US20100055119A1/en not_active Abandoned
- 2007-03-09 NZ NZ570708A patent/NZ570708A/xx not_active IP Right Cessation
- 2007-03-09 EP EP07705325.4A patent/EP2004676B1/en active Active
- 2007-03-09 PL PL11167363T patent/PL2392587T3/pl unknown
- 2007-03-09 JP JP2008558877A patent/JP2009529570A/ja active Pending
- 2007-03-09 UA UAA200811993A patent/UA97800C2/uk unknown
- 2007-03-09 CN CN201410764104.XA patent/CN104558126B/zh not_active Expired - Fee Related
- 2007-03-09 DK DK07705325.4T patent/DK2004676T3/da active
- 2007-03-09 EA EA200870342A patent/EA019733B1/ru not_active IP Right Cessation
- 2007-03-09 BR BRPI0708708-0A patent/BRPI0708708A2/pt not_active Application Discontinuation
- 2007-03-09 MX MX2008011520A patent/MX2008011520A/es active IP Right Grant
- 2007-03-09 CA CA002645342A patent/CA2645342A1/en not_active Abandoned
- 2007-03-09 DK DK11167363.8T patent/DK2392587T3/da active
- 2007-03-09 AP AP2008004609A patent/AP3642A/xx active
- 2007-03-09 ES ES11167363.8T patent/ES2573105T3/es active Active
- 2007-03-09 AU AU2007226430A patent/AU2007226430B2/en not_active Ceased
- 2007-03-09 WO PCT/GB2007/000812 patent/WO2007104932A2/en not_active Ceased
- 2007-03-09 AP AP2015008680A patent/AP2015008680A0/xx unknown
- 2007-03-09 SG SG201101721-7A patent/SG170092A1/en unknown
- 2007-03-09 KR KR1020087024478A patent/KR20080106467A/ko not_active Ceased
-
2008
- 2008-08-18 NO NO20083576A patent/NO20083576L/no not_active Application Discontinuation
- 2008-09-08 IL IL193965A patent/IL193965A0/en unknown
-
2012
- 2012-05-02 IL IL219544A patent/IL219544A0/en unknown
- 2012-06-18 US US13/526,467 patent/US8992934B2/en active Active
- 2012-09-05 JP JP2012194829A patent/JP2013040172A/ja active Pending
-
2014
- 2014-08-04 JP JP2014158545A patent/JP6422698B2/ja active Active
-
2015
- 2015-03-12 US US14/656,690 patent/US9675686B2/en active Active
-
2017
- 2017-05-05 US US15/588,476 patent/US10034933B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11439702B2 (en) | Influenza peptides and compositions | |
| US10034933B2 (en) | HIV and immunogenic peptide sequences and compositions | |
| CN101400693A (zh) | Hiv的调节或辅助蛋白的肽、组合物及它们的应用 | |
| AU2013201008B2 (en) | Peptide sequences and compositions | |
| HK1171027B (en) | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |